重视变应性鼻炎药物治疗的规范化和个体化

doi:10.6040/j.issn.1673-3770.0.2017.138

Abstract

Abstract: The prevalence of allergic rhinitis has increased in recently years. Pharmacotherapy is the main method to control the symptoms for the treatment of allergic rhinitis. A wide array of medical treatment options is available. Each drug has a different effect and speciality. Algorithms for management of allergic rhinitis AR and selection of drug should be based on each patients specific symptoms, and the presence of any comorbidities. Patient should be monitored to assess symptom control, therapy adjustment(step up/step down)is also needed.

Key words: Individualization, Allergic rhinitis, Pharmacotherapy

CLC Number:

R765.21

XU Yu， TAO Zezhang. Pharmacotherapeutic strategies for allergic rhinitis:Ithe importance of individualization and normalization.[J].JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 4-8.

References

[1] Wang XD, Zheng M, Lou HF, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011[J]. Allergy, 2016, 71(8):1170-1180.
[2] Juniper EF, Guyatt GH, O'Byrne PM, et al. Aqueous beclomethasonediproprionate nasal spray: regular versus “as required” use in the treatment of seasonal allergic rhinitis[J]. J Allergy Clin Immunol, 1990, 86(3):380-386.
[3] Juniper EF, Guyatt GH, Archer B, et al. Aqueous beclomethasonedipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of “as needed” use[J]. J Allergy Clin Immunol, 1993, 92(1 Pt 1):66-67.
[4] Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed(prn)[J]. Ann Allergy Asthma Immunol, 2003, 91(1):44-48.
[5] Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials[J]. BMJ, 1998, 317(7173):1624-1629.
[6] Yá(~overn)ez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis[J]. Ann Allergy Asthma Immunol, 2002, 89(5):479-484.
[7] Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class[J]. Ann Allergy Asthma Immunol, 2010, 104(1):13-29.
[8] Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis[J]. Am J Med, 2004, 116(5):338-344.
[9] Bielory L, Chun Y, Bielory BP, et al. Impact of mometasonefuroate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis[J]. Allergy, 2011, 66(5):686-693.
[10] Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthmaoutcomes in allergic rhinitis: a meta-analysis[J]. Allergy, 2013, 68(5):569-579.
[11] Ratner PH, Meltzer EO, Teper A. Mometasonefuroate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2009, 73(5):651-657.
[12] Allen DB, Meltzer EO, Jr LR, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year[J]. Allergy Asthma Proc, 2002, 23(6):407-413.
[13] Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasonefuroate aqueous nasal spray[J]. Pediatrics, 2000, 105(2):E22.
[14] Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray(mometasonefuroate)on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids[J]. Auris Nasus Larynx, 2013, 40(3):277-281.
[15] Simons FE. Advances in H1-antihistamines[J]. New Eng J Med, 2004, 351(21):2203-2217.
[16] Dizdar EA, Sekerel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2007, 71(6):843-849.
[17] Laekeman G, Simoens S, Buffels J, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice[J]. Respir Med, 2010, 4(5):615-625.
[18] Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(Suppl 1):S1-S43.
[19] Horak F, Zieglmayer UP, Zieglmayer R, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy[J]. Curr Med Res Opin, 2006, 22(1):151-157.
[20] Kaliner MA, Berger WE, Ratner PH, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis[J]. Allergy Asthma Immunol, 2011, 106(Suppl 2):S6-S11.
[21] Laforce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine[J]. Ann Allergy Asthma Immunol, 2004, 93(2):154-159.
[22] Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2009, 103(5):373-380.
[23] Carr WW, Ratner P, Munzel U, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis[J]. Allergy Asthma Proc, 2012, 33(6):450-458.
[24] Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review[J]. Drugs, 2007, 67(6):887-901.
[25] Van AJ, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period[J]. Allergy, 2003, 58(58):1268-1276.
[26] Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions[J]. Pediatr Pulmonol, 2009, 44(6):568-579.
[27] Mösges R, Klimek L. Todays allergic rhinitis patients are different: new factors that may play a role[J]. Allergy, 2007, 62(9):969-975.
[28] Anolik R. Clinical benefits of combination treatment with mometasonefuroate nasal spray and loratadinevsmonotherapy with mometasonefuroate in the treatment of seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(3):264-271.
[29] Can D, Tanaç R, Demir E, et al. Is the usage of intranasal glucocorticosteroids alone in allergic rhinitis sufficient?[J]. Allergy Asthma Proc, 2006, 27(3):248-253.
[30] Nasser M, Fedorowicz Z, Aljufairi H, et al. Antihistamines used in addition to topical nasal steroids for intermittent and persistent allergic rhinitis in children[J]. Cochrane Database Syst Rev, 2010, 7(7):CD006989.
[31] Hilberg O. Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge[J]. Allergy, 1995, 50(8):683-688.
[32] Ratner PH, Hampel F, Bavel JV, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(1):74-81.
[33] Hampel FC, Ratner PH, Van BJ, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device[J]. Ann Allergy Asthma Immunol, 2010, 105(2):168-173.
[34] Laforce CF, Carr W, Tilles SA, et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis[J]. Allergy Asthma Proc, 2010, 31(2):132-140.
[35] Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis[J]. J Allergy Clin Immunol, 2012, 129(129):1282-1289.e10.
[36] Rael EL, Ramey J, Lockey RF. Oxymetazoline hydrochloride combined with mometasone nasal spray for persistent nasal congestion(pilot study)[J]. World Allergy Organ J, 2011, 4(3):65-67.
[37] Meltzer EO, Bernstein DI, Prenner BM, et al. Mometasonefuroate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis[J]. Am J Rhinol Allergy, 2013, 27(2):102-108.
[38] Cingi C, Gunhan K, Gage-White L, et al. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis[J]. Laryngoscope, 2010, 120(9):1718-1723.
[39] Rodrigo GJ, Ya(~overn)ez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials[J]. Ann Allergy Asthma Immunol, 2006, 96(6):779-786.
[40] Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis.[J]. J Asthma, 2009, 46(9):878-883.
[41] Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall[J]. Ann Allergy Asthma Immunol, 2002, 88(6):592-600.
[42] Esteitie R, Detineo M, Naclerio RM, et al. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2010, 105(2):155-161.
[43] Goh BS, Ismail MI, Husain S. Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a randomised, double-blind, placebo-controlled study[J]. J Laryngol Otol, 2014, 128(3):242-248.
[44] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志, 2016, 51(1):6-24. Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis[J]. Chin J Otorhinolaryngol Head Neck Surg, 2016, 51(1):6-24.
[45] Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions.[J]. Allergy Asthma Proceed, 2013, 34(4):301-311.
[46] Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA(2)LEN and AllerGen)[J]. Allergy, 2008, 63(Suppl 86):8-160.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	ZHAO Li-min, NI Kun, WU Jia-li, CHEN Shu-mei, LI Xiao-yan. Etiology and treatment of inspiratory laryngeal stridor in infants[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 49 -51 .
[2]	SHI Chun-sheng1, ZHANG Qing-quan2， WANG Qiang2, SUN Yan2, GE Chang-yi1. Application of flaps in the reconstruction of soft palate defects[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 86 -88 .
[3]	ZHANG Ling1, SUN Chuan-yi1, XU An-ting2. 1 case of petrous apex cholesteatoma deafness patients[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 93 -94 .
[4]	. [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 1 -3 .
[5]	LUO Hui-xiu, FAN Chun-tao, DENG Yan-hua. Therapeutic effects of adenoidectomy and tonsillectomy in children with obstructive sleep apnea hypopnea syndrome[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 17 -20 .
[6]	HAO Ying-juan1, YANG Qing-song2, ZHOU Yue-hua2, YI Sheng-ping1， ZHAI Chang-bin2. Characteristics of thin corneal flaps created with Wavelight FS200 femtosecond laser[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 26 -31 .
[7]	WEN Hua-ming1, LI Hai-xiang2. Application of trianglar function method to calculate intra ocular lens power after myopic laser in situ keratomileusis[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(5): 74 -76 .
[8]	ZHU Jian， HE Qing-qing， ZHENG Lu-ming， FAN Zi-yi， ZHAO Guo-wei， HOU Lei， SHI Hou-bin. Clinical analysis for 57 re-operational cases of differentiated thyroid cancer[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(6): 9 -12 .
[9]	LI Shao-hua, SUN Yi-fan, LU Biao-qing. Application of double vascularized soft tissue flap in open radical mastoidectomy[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(1): 6 -7 .
[10]	WEI Xi-jian1, YIN Rui-lan2, GUO Xing3. Expression of a proliferation-inducing ligand in laryngeal squamous cell carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(1): 14 -16 .

Pharmacotherapeutic strategies for allergic rhinitis:Ithe importance of individualization and normalization.

PDF (PC)

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

[1]	WANG Tan, WU Ke, LI Lianqing, GONG Lili. Factors associated with systemic adverse reactions after subcutaneous immunotherapy injections and treatment options [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 71-74.
[2]	LU Hangui, LIN Xinsheng, YAO Danmian, WEI Yongxin, LI Chuangwei. Expression of IL-35 in allergic rhinitis and its effect on the immunoregulation of T cells [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 66-70.
[3]	PU Hongbo, DU Xiaodong. Allergen test results in 2 000 patients with allergic rhinitis in Wuxi District [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(4): 105-107.
[4]	CHEN Ming, YU Xuefei. Opinions on the treatment of chronic rhinosinusitis with allergic rhinitis [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(3): 18-22.
[5]	WU Xiangping. Influence of patient management on the clinical effect of sublingual dermatophagoides farinae drops in patients [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(3): 68-72.
[6]	LI Song, WANG Zonggui, YANG Jingpu, ZHANG Zhuping. Progress of transnasal endoscopic vidian neurectomy [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(1): 72-76.
[7]	ZHI Lili, SONG Daoliang. Expressions of eosinophils and IL5 in antrochoanal polyps and nasal polyps. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 43-46.
[8]	WAN Wenjin, WANG Wen, CHENG Lei. A meta-analysis of subcutaneous immunotherapy and sublingual immunotherapy in the treatment of dust mite-allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 103-108.
[9]	SHI Li, ZHAO Li, ZHANG Hongping. Long-term anti-inflammatory treatment of allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 9-12.
[10]	LIU Jing. Treatment of allergic rhinitis using syndrome differentiation based on the concept of “holism” in TCM. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 28-30.
[11]	CHENG Lei, QIAN Junjun, TIAN Huiqin. Research progresses on allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 1-3.
[12]	LI Lizhu, WU Qing, YI Xin, TIAN Li. Research progress on the animal model of allergic rhinitis in traditional Chinese medicine. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 60-63.
[13]	SHA Jichao, ZHANG Ce, ZHU Dongdong. Immunocompetence of nasal epithelial cells in allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 55-59.
[14]	XIANG Nan, ZHANG Qinxiu. Experience of professor Zhang Qinxiu in the treatment of perennial allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 100-102.
[15]	LIU Huaitao, MA Ruixia, CHENG Lei. Surgical treatment of refractory allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 18-21.